1. Home
  2. DTIL vs TTRX Comparison

DTIL vs TTRX Comparison

Compare DTIL & TTRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Precision BioSciences Inc.

DTIL

Precision BioSciences Inc.

HOLD

Current Price

$5.62

Market Cap

128.8M

Sector

Health Care

ML Signal

HOLD

TTRX

Turn Therapeutics Inc.

N/A

Current Price

$3.60

Market Cap

116.0M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
DTIL
TTRX
Founded
2006
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
128.8M
116.0M
IPO Year
2019
N/A

Fundamental Metrics

Financial Performance
Metric
DTIL
TTRX
Price
$5.62
$3.60
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
1
Target Price
$60.00
$8.00
AVG Volume (30 Days)
180.7K
14.1K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,070,000,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$34.30
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.53
$2.57
52 Week High
$8.82
$5.98

Technical Indicators

Market Signals
Indicator
DTIL
TTRX
Relative Strength Index (RSI) 73.04 48.74
Support Level $4.50 $3.55
Resistance Level $5.80 $4.01
Average True Range (ATR) 0.36 0.22
MACD 0.16 0.04
Stochastic Oscillator 79.86 41.18

Price Performance

Historical Comparison
DTIL
TTRX

About DTIL Precision BioSciences Inc.

Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.

About TTRX Turn Therapeutics Inc.

Turn Therapeutics Inc is a clinical-stage biotechnology company focused on developing pharmaceutical and medical device products for dermatology, wound care, and infectious disease. The company's proprietary platform technology, called PermaFusion, enhances drug performance by improving the stability and bioavailability of active pharmaceutical ingredients, which allows for reduced doses and fewer side effects. Its primary development programs target skin conditions such as moderate to severe eczema and onychomycosis.

Share on Social Networks: